Name | Pexidartinib |
---|---|
Synonyms |
PLX3397
5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)-3-pyridinyl]methyl}-2-pyridinamine 3-Pyridinemethanamine, N-[5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)- N-[5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-2-pyridinyl]-6-(trifluoromethyl)-3-pyridinemethanamine PLX-3397 pexidartinib |
Description | Pexidartinib (PLX-3397) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13 nM, 27 nM, and 11 nM for CSF1R, c-Kit, and FLT3, respectively. |
---|---|
Related Catalog | |
Target |
IC50: 28 nM (c-Fms), 16 nM (c-Kit) |
In Vivo | Pexidartinib is a potent drug for treatment of cancer and used for Phase III TGCT clinical trial[1]. |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 580.0±50.0 °C at 760 mmHg |
Molecular Formula | C20H15ClF3N5 |
Molecular Weight | 417.815 |
Flash Point | 304.6±30.1 °C |
Exact Mass | 417.096802 |
PSA | 66.49000 |
LogP | 4.77 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.662 |
Storage condition | -20℃ |
Hazard Codes | N |
---|